Publication | Closed Access

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

First-line TherapySakk 19/05MedicineMetronomic TherapyPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerPlatinum-based Chemotherapy